Stocks and Investing
Stocks and Investing
Tue, July 7, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, July 6, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mayank Mamtani Upgraded (ACST) to Strong Buy and Held Target at $96 on, Jul 6th, 2020
Mayank Mamtani of B. Riley Securities, Upgraded "Acasti Pharma Inc." (ACST) to Strong Buy and Held Target at $96 on, Jul 6th, 2020.
Mayank has made no other calls on ACST in the last 4 months.
There is 1 other peer that has a rating on ACST. Out of the 1 peers that are also analyzing ACST, 0 agree with Mayank's Rating of Hold.
This is the rating of the analyst that currently disagrees with Mayank
- Nathan Weinstein of "Aegis Capital" Maintained at Strong Buy with Decreased Target to $103 on, Wednesday, May 6th, 2020
Contributing Sources